argenx reports positive Phase 3 ALKIVIA topline results
argenx (ARGX) announces positive topline results from its Phase 3 ALKIVIA trial of efgartigimod in autoimmune myositis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.